Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.13 +1.80%
EPS Growth %: +60.7%
Financial Fact:
Total revenue: 12.54M
Today's EPS Names:
CRWS, MEI, PODC, More
EPS Growth %: +60.7%
Financial Fact:
Total revenue: 12.54M
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
Note: EPS may not be comparable
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $7.53 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS
- JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
